[Click eStock] "Syntekabio, Leading Domestic AI Drug Development Platform Company"

ResearchAlum analyzed on the 25th that Syntekabio requires attention as the only domestic artificial intelligence (AI) drug development platform.

Researcher Kim Jaemu of ResearchAlum explained, "Using AI can drastically reduce the time and cost involved in drug development," adding, "In addition to global pharmaceutical companies, big tech companies are actively entering AI drug development."

He continued, "AI technology is being applied in various fields such as target discovery candidate substance derivation, clinical trials, and repurposing of existing drugs through mergers and acquisitions (M&A) and collaborations," and added, "Alphabet, Google's parent company, established an AI drug development company (Isomorphic Labs) in 2021."

He emphasized, "NVIDIA invested $50 million in Recursion in July last year, and in August of the same year, invested in unlisted companies Genesis Therapeutics and Superluminal Medicine." Furthermore, he analyzed, "Cases of big tech companies making large-scale investments in AI drug development or collaborating with related companies are increasing, and within this trend, Syntekabio's drug development platform is expected to be monetized in earnest."

Researcher Kim said, "Recently, Novo Nordisk signed a contract with French company Eviden and NVIDIA to produce supercomputers equipped with new NVIDIA chips to accelerate AI-based drug development," explaining, "Infrastructure investment for large-scale computation is essential."

He also added, "Syntekabio owns 3,300 units of the MAHASupercom supercomputer specialized in bioinformatics analysis," and "plans to increase this to 5,000 units by the first half of this year." He stated, "The ABS (AIBioSupercom) Center, completed at the end of last year, can host up to 10,000 units," and "depending on demand, the construction of 2nd and 3rd centers and the addition of high-performance chips will continuously improve computing power."